Drug intelligence / Profile preview

ciprofloxacin + cefixime + cefuroxime

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular, Ophthalmic

Overview

This is a combination of three antibiotics: ciprofloxacin (a fluoroquinolone), cefixime (a third-generation cephalosporin), and cefuroxime (a second-generation cephalosporin). Ciprofloxacin works by inhibiting bacterial DNA replication, while cefixime and cefuroxime are cephalosporins that inhibit bacterial cell wall synthesis. This specific three-drug combination is not a standard commercial product.

Targets

PBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on ciprofloxacin + cefixime + cefuroxime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + cefixime + cefuroxime.

Explore the full profile